Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

EMA Starts Review of Tredaptive, Pelzont, Trevaclyn Medicines

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/21/2012 | 11:46am CET

LONDON--The European Medicines Agency, or EMA, Friday said it has started a review of the safety and efficacy of Tredaptive, Pelzont and Trevaclyn, identical medicines that are used to treat adults with dyslipidaemia, particularly combined mixed dyslipidaemia and primary hypercholesterolaemia.

MAIN FACTS:

-Review was triggered because the Agency was informed by the pharmaceutical company Merck, Sharp & Dohme of the preliminary results of a large, long-term study comparing the clinical effects of adding these medicines to statins (standard medicines used to reduce cholesterol) with statin treatment alone.

-Study raises questions about the efficacy of the medicine when added to statins, as this did not reduce the risk of major vascular events compared with statin therapy alone.

-Preliminary results saw a higher frequency of non-fatal but serious side effects in patients taking the medicines than in patients only taking statins.

-Pharmacovigilance Risk Assessment Committee (>> PRODUCTIVITY TECHS CORP) will assess the data and make a recommendation to the Committee on Medicinal Products for Human Use (>> Champion Industries, Inc.), which will issue an opinion on the regulatory action required.

-Opinion is expected in January 2013.

-Write to Tapan Panchal at tapan.panchal@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : PRODUCTIVITY TECHS CORP, Champion Industries, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
02/26 MERCK : Letermovir, an Investigational Antiviral Medicine for Prevention of Cyto..
02/24 MERCK : In First Phase 3 Trial, Merck’s Investigational Inactivated Varice..
02/24 MERCK : Study Findings from Merck & Company Broaden Understanding of Hepatitis C..
02/24 RECENT STUDIES FROM MERCK & COMPANY : A...
02/24 MERCK : Announces EPOCH Study of Verubecestat for the Treatment of People with M..
02/24 MERCK : New Data from Merck & Company Illuminate Findings in Immunoglobulins (Tr..
02/24 MERCK : Study Results from Merck & Company in the Area of Vaccines Reported (Des..
02/24 MERCK : Research Data from Merck & Company Update Understanding of Hypertension ..
02/24 DATA FROM MERCK & COMPANY ADVANCE KN : a snapshot of recent data in pediatric an..
02/24 MERCK : Researchers at Merck & Company Report New Data on Melanoma (Population P..
More news
Sector news : Pharmaceuticals - NEC
02/24DJSHIRE : Files 8K - Other Events
02/24DJASTRAZENECA : Hyperkalaemia Drug Clears Scientific Hurdle for European Approval
02/24DJASTRAZENECA : Gets Approval for Drug Treating Hyperkalaemia
02/23DJPFIZER : Files 8K - Changes Executive Management
02/23DJGlaxoSmithKline Reports Positive Study Results for Asthma Drug
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/26 BIOTECH FORUM DAILY DIGEST : Can Aerie Pharmaceuticals Continue To Rally? Spotli..
02/24 Merck's VZV vaccine candidate successful in first late-stage study in immunoc..
02/24 SYNERGY : 3 Scenarios, 1 Choice
02/24 I'M SICK AND TIRED OF GILEAD SCIENCE : Part 2
02/23 Merck to take $2.9B charge related to uprifosbuvir
Advertisement
Financials ($)
Sales 2017 39 712 M
EBIT 2017 13 517 M
Net income 2017 8 459 M
Debt 2017 4 774 M
Yield 2017 2,84%
P/E ratio 2017 20,23
P/E ratio 2018 17,19
EV / Sales 2017 4,71x
EV / Sales 2018 4,56x
Capitalization 182 412 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 68,7 $
Spread / Average Target 3,8%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.11.86%182 412
JOHNSON & JOHNSON5.63%333 891
ROCHE HOLDING LTD.5.98%210 192
PFIZER INC.4.86%207 902
NOVARTIS AG4.72%202 648
SANOFI4.79%109 848
More Results